Celltech, Biogen CDP 571 deal

Celltech (LSE:CCH; CLL) and Biogen (BGEN) partnered to develop CCH's Phase III CDP 571 humanized anti-TNF-alpha antibody to treat Crohn's disease. The companies will share ongoing research, development, manufacturing and commercialization costs, and BGEN will take over manufacturing after product launch. Both parties will share profits and promote the treatment in the U.S. and Europe, except Italy where CCH has sole commercial rights. The companies also will explore the use of CDP 571 in additional inflammatory conditions, such as psoriasis. ...